HealthLynked (HLYK): An Under-the-Radar Healthcare AI Story Just Got Very Interesting

 

A new enterprise pilot with Palm Beach Accountable Care Organization could give investors a reason to take a closer look at this small-cap healthcare AI company.

​

INVESTOR AWARENESS ARTICLE  •  SEPTEMBER 21, 2026  •  OTCQB: HLYK

​

Artificial intelligence may be the biggest investment theme in the market, but healthcare AI is still in the early stages of determining where the technology will actually create measurable economic value.

​

Diagnostics gets attention. Drug discovery gets attention. AI-generated medical information gets attention.

​

But there is another enormous opportunity hiding in plain sight: the hundreds of millions of interactions required to move patients through the healthcare system every year.

​

Phone calls. Scheduling. Finding physicians. Patient onboarding. Insurance information. Check-in. Follow-up. Care coordination. Patient communication.

​

HealthLynked Corp. (OTCQB: HLYK) is building its AI strategy around that problem - and a recently announced enterprise pilot may be the strongest reason yet for investors to put HLYK on their radar.​

​

THE INVESTOR HOOK

HealthLynked is moving from developing healthcare AI tools to testing them inside a large, real-world value-based care organization. The key question now is whether measurable enterprise results can become a repeatable commercialization model.

 

HealthLynked Is Moving Its AI Into the Real World

​

HealthLynked recently announced a strategic enterprise pilot with Palm Beach Accountable Care Organization (PBACO) to evaluate its AI-powered patient engagement, care coordination, intelligent scheduling and healthcare workflow technology.

​

PBACO supports approximately 10,000 physicians and healthcare professionals serving more than 325,000 Medicare beneficiaries across 32 states and Washington, D.C.

​

That scale makes this substantially more interesting than another healthcare company announcing a new AI feature. HealthLynked now has an opportunity to demonstrate whether its technology can produce measurable value inside a sophisticated healthcare organization.

​

And that is where the HLYK investment story starts to get interesting.

​

What Exactly Is Being Tested?

​

HealthLynked is not testing a single chatbot. The PBACO pilot incorporates an integrated suite of technologies designed to automate and improve many of the repetitive interactions occurring between medical practices and patients.

​

• HealthLynked AI Care Agent

• 24/7 AI-powered patient call management

• Intelligent appointment scheduling

• Digital patient onboarding

• QR-code patient check-in

• Secure patient communications

• Provider workflow tools

• Digital care coordination

• Population-health engagement

 

The AI Care Agent is designed to act as a digital extension of a physician office - helping answer patient calls, onboard new patients, collect demographic and insurance information, schedule and manage appointments, help patients locate physicians and specialists, answer routine administrative questions, and provide reminders and follow-up communications.

​

Every medical practice has phones. Every practice schedules appointments. Every practice onboards patients. Every practice collects information. Every practice answers repetitive questions. Every practice has employees spending time on administrative work rather than patient care.

​

HealthLynked is attempting to automate that layer of healthcare.

​

Why the PBACO Pilot Could Matter Far Beyond PBACO

​

For investors, the most important part of the announcement may not be the initial deployment. It is what happens if the model works.

The pilot is intended to measure areas including patient engagement, scheduling efficiency, administrative workload, satisfaction, care coordination and operational efficiency. Those measurements can create something particularly valuable for a small healthcare technology company: proof of return on investment.

​

THE COMMERCIALIZATION MODEL

Deploy  →  Measure  →  Demonstrate ROI  →  Expand  →  Replicate

 

Enterprise healthcare sales become easier when a company can move from saying that its technology should improve efficiency to showing prospective customers measurable results from a real implementation. A successful PBACO deployment could therefore become more than one customer relationship - it could become a reference implementation.

​

HealthLynked has identified a broader potential enterprise market that includes accountable care organizations, Medicare Advantage plans, commercial insurers, physician groups, clinically integrated networks, employer health plans and health systems.

​

That is the scalability question HLYK investors should be watching.

​

Healthcare AI Doesn't Have to Diagnose Cancer to Be Valuable

​

One of the more interesting aspects of HealthLynked's strategy is that it does not require AI to replace physicians or make extraordinarily complex clinical decisions.

​

Some of the biggest inefficiencies in healthcare are remarkably mundane: patients cannot get through on the phone, they do not know which physician to see, appointments are not scheduled efficiently, forms are incomplete, medical information is fragmented, follow-up is missed, and staff members spend hours performing repetitive administrative tasks.

​

Those problems occur millions of times across the healthcare system. Solving even a fraction of them has economic value.

​

In value-based care, that value can become especially important because organizations are financially motivated to improve coordination, increase efficiency, and manage the overall cost and quality of care. That makes PBACO a potentially strong environment for HealthLynked to demonstrate what its technology can do.

​

Then There Is the Founder

​

HealthLynked founder, Chairman and CEO Michael Dent, M.D., has previously built a public healthcare company - although in a different segment of the industry.

​

Dent founded NeoGenomics Laboratories and served as its Chairman and CEO. NeoGenomics subsequently developed into a Nasdaq-listed oncology diagnostics company.

​

That history does not mean HealthLynked will follow the same trajectory. The businesses, markets and risks are different. But founder history matters, particularly in a small public company.

​

Dent is not approaching the intersection of healthcare, technology and public markets for the first time.

​

HealthLynked is now applying that experience to another emerging healthcare opportunity: AI-powered patient engagement and the infrastructure connecting patients, providers and healthcare organizations.

​

This Is Not Another Hims or Teladoc Story

​

Investors following digital health already know the major public names. But trying to frame HealthLynked simply as another Hims & Hers or Teladoc may miss the point.

​

HealthLynked is pursuing a different layer of the digital healthcare stack: infrastructure that can help healthcare organizations interact with patients more efficiently.

​

The thesis is not that HLYK is directly comparable to those companies. The thesis is that healthcare digitization has created multiple valuable layers - and HealthLynked is targeting the AI-powered engagement and workflow layer.

​

The Part Investors Should Watch Closely

​

The PBACO announcement does not prove the HealthLynked thesis. It gives HealthLynked an opportunity to prove it.

​

HLYK remains a small OTCQB-listed company. Small-cap securities can carry substantial financing, execution, liquidity and commercialization risk, and HealthLynked still needs to demonstrate that enterprise interest translates into meaningful recurring revenue.

​

Investors considering HLYK should watch several specific developments:

​

• Results and measurable performance from the PBACO pilot.

• Expansion of HealthLynked technology across additional PBACO practices.

• Evidence that AI automation reduces administrative workload or improves patient access.

• Additional ACO, insurer, physician-group or enterprise contracts.

• Growth of recurring technology revenue relative to HealthLynked's traditional healthcare operations.

• Evidence that one enterprise deployment can be replicated efficiently across multiple organizations.

 

THE QUESTION FOR INVESTORS

Is HealthLynked building an interesting collection of healthcare technologies - or the foundation of a scalable enterprise healthcare AI platform?

 

Why HLYK May Be Worth Putting on the Watchlist

​

There are thousands of small public companies promising to participate in the AI revolution. Far fewer have a physician founder who previously founded a Nasdaq-listed healthcare company.

​

Far fewer have spent years building healthcare connectivity infrastructure. And fewer still have the opportunity to test their AI technology with an organization supporting approximately 10,000 healthcare professionals and more than 325,000 Medicare beneficiaries.

​

That is why the PBACO announcement deserves attention.

​

The opportunity for HLYK is not simply to build another AI application. It is to demonstrate that artificial intelligence can become part of the operating infrastructure connecting patients with healthcare.

​

If HealthLynked can prove that model with PBACO - and then replicate it - the company investors are looking at a year from now could be substantially different from the small healthcare technology company they are looking at today.

​

That is what makes HLYK worth watching now.

​

Sources

• HealthLynked Corp., September 21, 2026 announcement regarding the strategic enterprise pilot with Palm Beach Accountable Care Organization.

• HealthLynked Corp. filings with the U.S. Securities and Exchange Commission regarding company leadership, business strategy and risk factors.

• HealthLynked corporate materials describing its AI Care Agent, patient engagement platform and enterprise healthcare strategy.

 

IMPORTANT DISCLOSURE

This material is promotional/investor-awareness content regarding HealthLynked Corp. and is provided for informational purposes only. It is not investment advice or a recommendation to buy or sell any security. HealthLynked is an emerging small-cap company whose securities may involve substantial risk, volatility and limited liquidity. Investors should review HealthLynked's filings with the U.S. Securities and Exchange Commission and conduct their own due diligence before making any investment decision. Statements regarding future performance, commercialization, enterprise adoption, scalability or growth are forward-looking and actual results may differ materially

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.

​